#1 Clinical Trials Search in Europe

Pentixafor Gallium Ga-68

Pentixafor Gallium Ga-68 is an innovative radiopharmaceutical being studied in clinical trials for its potential in diagnosing and evaluating multiple myeloma. This article explores how this compound is being used to detect and assess multiple myeloma lesions, comparing its effectiveness to traditional imaging methods, and evaluating its impact on patient care and treatment outcomes.

Table of Contents

What is PENTIXAFOR GALLIUM GA-68?

PENTIXAFOR GALLIUM GA-68, also known as [68Ga]Ga-PentixaFor, is an innovative imaging agent being studied for its potential in detecting and evaluating multiple myeloma[1]. It is a radioactive substance used in a special type of imaging called PET (Positron Emission Tomography) scans.

How does it work?

This imaging agent works by targeting a specific protein called CXCR4, which is often found in high amounts on multiple myeloma cells. When injected into the body, PENTIXAFOR GALLIUM GA-68 attaches to these proteins, allowing doctors to see where the cancer cells are located using a PET scanner[1].

What is it used for?

PENTIXAFOR GALLIUM GA-68 is being investigated for several uses in multiple myeloma patients:

  • Initial staging: Helping doctors determine the extent of the disease when a patient is first diagnosed[1]
  • Detection of minimal residual disease: Finding small amounts of cancer cells that may remain after treatment[1]
  • Therapeutic evaluation: Assessing how well a treatment is working[2]
  • Relapse detection: Identifying if and where the cancer has returned in patients who have previously been treated[2]

Ongoing Clinical Trials

There are currently two clinical trials studying PENTIXAFOR GALLIUM GA-68 for multiple myeloma:

  1. A study focusing on patients under 66 years old who are eligible for stem cell transplantation[1]
  2. A study including both newly diagnosed patients and those experiencing a relapse[2]

These trials aim to determine how sensitive and accurate PENTIXAFOR GALLIUM GA-68 PET scans are compared to other imaging methods like FDG-PET (which uses a different radioactive tracer) and MRI[1][2].

Potential Benefits

Researchers hope that PENTIXAFOR GALLIUM GA-68 PET scans may offer several advantages:

  • More accurate detection of multiple myeloma lesions, including those in the bone marrow and outside the bones (called extramedullary disease)[1]
  • Better ability to predict a patient’s prognosis based on the number and intensity of detected lesions[1][2]
  • Improved monitoring of how well treatments are working[2]
  • Potential to detect very small amounts of remaining cancer cells after treatment, which could help guide further therapy decisions[1]

Administration and Safety

PENTIXAFOR GALLIUM GA-68 is given as an injection into a vein (intravenously). The maximum dose being studied is 200 MBq (megabecquerels, a unit of radioactivity)[1][2]. After the injection, patients typically undergo a PET scan about 60 minutes later.

The clinical trials are carefully monitoring patients for any side effects or reactions to the imaging agent. Patients are observed for at least an hour after the injection, with measurements of heart rate, blood pressure, and oxygen levels taken at various time points[1][2].

It’s important to note that while PENTIXAFOR GALLIUM GA-68 shows promise, it is still being studied and is not yet approved for routine clinical use. Patients interested in this imaging technique should speak with their healthcare providers about the possibility of participating in clinical trials.

Aspect Details
Drug Name Pentixafor Gallium Ga-68
Administration Intravenous injection, up to 200 MBq
Primary Use Diagnostic imaging for multiple myeloma
Study Objectives Determine sensitivity, specificity, and prognostic value in detecting multiple myeloma lesions
Comparison FDG-PET and other imaging methods
Patient Population Adults with symptomatic multiple myeloma, newly diagnosed or in relapse
Potential Benefits Improved lesion detection, better staging and treatment planning, MRD assessment
Safety Monitoring Clinical observation for 1 hour post-injection, vital signs monitoring

FAQ

  • What is Pentixafor Gallium Ga-68? Pentixafor Gallium Ga-68 is a radioactive compound used in PET scans to detect and evaluate multiple myeloma lesions. It's being studied as a potential improvement over current imaging techniques.
  • How is Pentixafor Gallium Ga-68 administered? Pentixafor Gallium Ga-68 is given as an intravenous injection. The dose is typically up to 200 MBq (megabecquerels), and patients are monitored for about an hour after the injection.
  • What are the main objectives of these clinical trials? The main objectives are to determine the sensitivity and specificity of Pentixafor Gallium Ga-68 PET in detecting multiple myeloma lesions, compare it to standard FDG-PET scans, and assess its prognostic value in patient outcomes.
  • Who is eligible for these clinical trials? Eligible participants are adults with symptomatic multiple myeloma requiring first-line treatment or in relapse. They must have adequate organ function and not have certain other medical conditions that could interfere with the study.
  • What are the potential benefits of using Pentixafor Gallium Ga-68? Pentixafor Gallium Ga-68 may offer improved detection of multiple myeloma lesions, potentially leading to better staging, treatment planning, and monitoring of the disease. It could also help in assessing minimal residual disease after treatment.

Ongoing Clinical Trials on Pentixafor Gallium Ga-68

  • Study on [68Ga]Ga-PentixaFor for Staging and Evaluation in Symptomatic Multiple Myeloma Patients in Initial Treatment or Relapse

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on [68Ga]Ga-PentixaFor for Detecting Multiple Myeloma in Patients Under 66 Eligible for Stem Cell Transplantation

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell that normally produces antibodies to fight infections.
  • PET (Positron Emission Tomography): An imaging test that uses a radioactive tracer to show how organs and tissues are functioning in the body.
  • FDG-PET: A type of PET scan that uses fluorodeoxyglucose (FDG) as the radioactive tracer, commonly used in cancer imaging.
  • Sensitivity: The ability of a test to correctly identify patients with a disease.
  • Specificity: The ability of a test to correctly identify people without the disease.
  • Prognostic impact: The effect of a factor (in this case, imaging results) on the likely course of a disease and patient outcomes.
  • Minimal Residual Disease (MRD): Small numbers of cancer cells that remain in the body during or after treatment.
  • Bone marrow (BM) lesions: Abnormal areas in the bone marrow that may indicate the presence of cancer cells.
  • Extra-medullary disease (EMD): The spread of multiple myeloma cells outside of the bone marrow to other tissues or organs.
  • SUV (Standardized Uptake Value): A measure of how much radioactive tracer is taken up by tissue, used to quantify PET scan results.

References

  1. http://clinicaltrials.eu/trial/study-on-68gaga-pentixafor-for-detecting-multiple-myeloma-in-patients-under-66-eligible-for-stem-cell-transplantation/
  2. http://clinicaltrials.eu/trial/study-on-68gaga-pentixafor-for-staging-and-evaluation-in-symptomatic-multiple-myeloma-patients-in-initial-treatment-or-relapse/